Looking forward, do you believe novel delivery systems in NMIBC could be easily adopted in clinical practices? What challenges do you anticipate in operationalizing TAR-200 and other novel delivery ...

“I feel a lot of providers, with Antiva being available, have unfortunately reserved use of this great FDA-approved agent for BCG-unresponsive patients because of the supply issue with BCG," says ...

Recent advancements in kidney stone management include novel access sheaths and miniaturized scopes, enhancing treatment options for patients. AI integration in kidney stone management offers ...

“It definitely makes it easier for providers [to counsel patients]," says Landon Trost, MD. With the FDA’s recent class-wide labeling changes for testosterone products 1, urologist Landon Trost, MD, ...

“The NIAGARA approval really begins to bring immunotherapy into the neoadjuvant setting," says Joshua J. Meeks, MD, PhD. “The NIAGARA approval really begins to bring immunotherapy into the neoadjuvant ...

"What we found is that 9% of women with a GSM-related diagnosis filled a prescription for vaginal estrogen during the study period, and these women tended to be younger," says Ekene Enemchukwu, MD, ...

“The benefit of being here at the University of Minnesota is that we have a bunch of different types of settings to be able to trial this," says Hailey Frye. A study from the American Urological ...

"We can improve urinary tract infections considerably with behavioral modification," says Anna Myers, CNP. In a recent interview with Urology Times ®, Anna Myers, CNP, was asked about preventing ...

Minimal WVTT with one treatment per lobe showed fewer post-operative complications and similar efficacy compared to multiple treatments per lobe. The study included 146 patients, with comparable ...

The study utilized 68Ga-PSMA-11 PET imaging to assess outcomes in prostate cancer patients treated with 177Lu-PSMA-617, focusing on whole-body SUVmean as a key parameter. Higher whole-body SUVmean ...

Experts discuss the unmet needs in the treatment of non–muscle-invasive bladder cancer (NMIBC), highlighting areas where advancements are still needed.

"We see the overall survival, whether it is [in] all-comers, in HRR gene mutation-positive patients, or in HRR gene [mutation]-negative patients or [those] who did not have mutations, the overall ...